A trial looking at a vaccine for breast cancer with HER2 (PRESENT)
Cancer type:
Status:
Phase:
This trial looked at a vaccine called Neuvax for breast cancer that has receptors for the HER2 protein and has spread to the
More about this trial
Doctors may test your breast cancer cells to see if they have a receptor for a protein called HER2.
Breast cancers that have a large number of these receptors are called HER2 positive. Doctors can treat positive breast cancer with a targeted drug called trastuzumab (Herceptin). But trastuzumab doesn’t work well for breast cancer that has low to moderate amounts of the HER2 receptor.
Neuvax is a vaccine. It combines a protein that is similar to the HER2 protein with a drug called . Doctors can use GM-CSF to stimulate the body’s The researchers hoped that Neuvax would stimulate the immune system to attack any remaining breast cancer cells in the body that have the HER2 protein after completing standard of care therapy.
In this trial some people have Neuvax and some people have GM-CSF. The researchers will compare the 2 groups.
The aims of this trial are to find out:
- how well Neuvax works for breast cancer that has spread to the lymph nodes and has low to moderate amounts of HER2 protein
- how safe Neuvax is
Summary of results
We contacted the trial team but there won't be results available for this trial.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Mary O'Brien
Supported by
Experimental Cancer Medicine Centre (ECMC)
Galena Biopharma
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
